BTIG analyst Mark Massaro maintained a Buy rating on BioNano Genomics (BNGO – Research Report) on January 5 and set a price target of $6.00. The company’s shares closed last Friday at $1.66.
Massaro covers the Healthcare sector, focusing on stocks such as Guardant Health, Cerus, and Exact Sciences. According to TipRanks, Massaro has an average return of -16.0% and a 30.80% success rate on recommended stocks.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for BioNano Genomics with a $6.33 average price target.
See today’s best-performing stocks on TipRanks >>
BNGO market cap is currently $64.47M and has a P/E ratio of -0.24.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
BioNano Genomics (BNGO) Company Description:
BioNano Genomics, Inc. is a life sciences instrumentation company, which focuses on genome analysis space. The firm engages in the development and marketing of Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline cytogenetics. The company was founded by Han Cao in October 2003 and is headquartered in San Diego, CA.
Read More on BNGO:
- Bionano Genomics announces OGM added to ISCN
- International Consortium Publishes Comprehensive Roadmap for the Clinical Implementation of OGM in Hematological Malignancy Applications
- Bionano Genomics announces publication of framework paper for OGM-Dx HemeOne
- Bionano Genomics upgrades optical genome mapping pipeline
- Bionano Announces Significant Upgrades to its Bionano Solve Pipeline and its VIA™ Software for OGM Data Analysis in Constitutional Genetic Disease Research